Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 332 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
332 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with refractory locally advanced or metastatic solid tumors limited to NSCLC, TNBC, HNSCC, esophageal (SCC/adenocarcinoma), gastric/GEJ adenocarcinoma, and gynecologic (cervical/endometrial/ovarian) cancers (ECOG 0–1) receive NRM-823, a bispecific T‑cell engager targeting CD3 and a novel tumor antigen, as monotherapy with dose escalation/expansion, with a cohort combining NRM-823 plus an immune checkpoint inhibitor. Primary focus is safety and RP2D determination, with preliminary antitumor activity assessment.
ClinicalTrials.gov ID: NCT07182149
TrialFetch AI summary: Adults with measurable advanced/metastatic breast cancer (progressed after ≥1 line endocrine therapy and a CDK4/6 inhibitor) or advanced/metastatic colorectal cancer (previously treated per standard options, plus one cohort without prior chemo for metastatic disease), ECOG 0–1. Participants receive oral investigational agent PF-08032562 (target/mechanism not publicly described) as monotherapy or combined with fulvestrant (breast) or cetuximab or FOLFOX + bevacizumab (colorectal) in 28-day cycles with dose escalation/expansion.
ClinicalTrials.gov ID: NCT07318805
TrialFetch AI summary: Enrolls adults with measurable advanced/metastatic breast cancer (primary focus; postmenopausal or on ovarian suppression, ECOG 0–1) and select other refractory advanced solid tumors; Part 1A includes heavily pretreated patients lacking standard options, while breast cancer expansion cohorts include patients with 1–3 prior metastatic lines or (in certain regions) CDK4/6-inhibitor–naïve and untreated for advanced disease. Tests oral BG-75202, a small-molecule KAT6A/KAT6B lysine acetyltransferase inhibitor, as monotherapy and in combination with endocrine therapy (estrogen receptor antagonist) and with CDK4 inhibition plus an aromatase inhibitor.
ClinicalTrials.gov ID: NCT07222267
TrialFetch AI summary: Enrolls adults with advanced malignancies, primarily HR+/HER2− advanced breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor (phase II limited to ≤2 prior endocrine lines for advanced disease and no prior chemotherapy/ADC in the advanced setting), with additional phase I cohorts for CCNE1-amplified solid tumors and metastatic castration-resistant prostate cancer. Patients receive the first-in-human investigational agent GVV858 (target/mechanism not publicly specified) as monotherapy or combined with endocrine therapy—fulvestrant (and letrozole in phase I), with phase II evaluating two GVV858 dose regimens plus fulvestrant.
ClinicalTrials.gov ID: NCT07288359
TrialFetch AI summary: Adults with metastatic or locally advanced solid tumors (including interest in TNBC) that have progressed after or are ineligible for standard therapy, with ECOG 0–1, measurable disease, adequate organ/cardiac function, and no significant cardiac disease/QTc prolongation, active >grade 1 neuropathy, or prior MMAE- or SORT1-targeted therapy. Participants receive PQ203, a once-weekly IV SORT1-targeting peptide–drug conjugate delivering the microtubule inhibitor MMAE to SORT1-expressing tumor cells, in dose-escalation/optimization to establish RP2D and assess preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07190469
TrialFetch AI summary: For adults with locally advanced or metastatic breast cancer (ECOG 0–1) previously treated with standard subtype-appropriate therapy (including prior endocrine therapy + CDK4/6 inhibitor for ER+/HER2−), enrolling molecularly defined cohorts: ER+/HER2−, ER+/HER2− with FGFR1 amplification, and luminal androgen receptor–subtype TNBC (AR ≥10% by IHC), generally with measurable disease and available tumor tissue. Patients receive oral BBI-940, a first-in-human kinesin molecular degrader designed to disrupt mitotic/ecDNA segregation, as monotherapy or (in ER+/HER2− without ESR1 mutation) in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07408089
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced/metastatic solid tumors, including ER+/HER2− breast cancer, NSCLC, CRPC, and MSS colorectal cancer after prior standard therapy, receive oral IDE574 monotherapy; breast cancer cohorts require prior endocrine therapy and CDK4/6 inhibitor. ER+/HER2− breast cancer patients may receive IDE574, an investigational dual KAT6/KAT7 epigenetic inhibitor, in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07540572
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808
TrialFetch AI summary: Open-label dose-escalation/expansion study of oral RGT-490 monotherapy, a selective mutant PI3Kα inhibitor, in adults with locally advanced unresectable or metastatic solid tumors harboring activating PIK3CA mutations after at least one prior therapy. Expansion focuses on HR+/HER2− advanced breast cancer; patients with prior PI3Kα inhibitor exposure or diabetes requiring antihyperglycemic medication are excluded.
ClinicalTrials.gov ID: NCT07524322